High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites
Holcapek M, et al.
Analytical and Bioanalytical Chemistry, 391(1), 59-78 (2008)
Screening of xanthine oxidase inhibitor from selected edible plants and hypouricemic effect of Rhizoma Alpiniae Officinarum extract on hyperuricemic rats
Lin L, et al.
Journal of functional foods, 50(1), 26-36 (2018)
Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9 (UGT1A9)
Kerdpin O, et al.
Drug Metabolism and Disposition, 50(1), 26-36 (2006)
Drug metabolism and disposition: the biological fate of chemicals, 34(10), 1742-1748 (2006-07-14)
Cytochrome P4503A4 (CYP3A4) is the principal drug-metabolizing enzyme in human liver. Drug-drug interactions (DDIs) caused by induction of CYP3A4 can result in decreased exposure to coadministered drugs, with potential loss of efficacy. Immortalized hepatocytes (Fa2N-4 cells) have been proposed as
Annals of the rheumatic diseases, 67(5), 609-613 (2007-08-31)
Uric acid lowering therapy (UALT) is considered a chronic treatment for gout. Relatively little is known about adherence to UALT. We assessed adherence with UALT over a 1-year study period among 9823 older adults enrolled in a pharmacy benefit program.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
